MedTrace Logo

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

NCT06223048 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-07-30

No results posted yet for this study

Summary

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).

Conditions

  • Primary Open Angle Glaucoma

Interventions

DRUG

AMDX-2011P

AMDX-2011P single bolus injection intravenous for diagnostic review

Sponsors & Collaborators

  • Amydis Inc.

    lead INDUSTRY

Principal Investigators

  • David Bingaman · Amydis Inc.

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-07
Primary Completion
2024-11-30
Completion
2025-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06223048 on ClinicalTrials.gov